Vericel (VCEL) Expected to Announce Quarterly Earnings on Thursday

Vericel (NASDAQ:VCEL) is expected to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $64.5680 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Vericel Stock Down 1.3%

VCEL stock opened at $36.25 on Wednesday. The company has a market cap of $1.83 billion, a price-to-earnings ratio of 302.11 and a beta of 1.39. The business has a fifty day simple moving average of $33.64 and a 200-day simple moving average of $37.74. Vericel has a 52 week low of $29.24 and a 52 week high of $63.00.

Analyst Upgrades and Downgrades

VCEL has been the subject of a number of research analyst reports. BTIG Research downgraded Vericel from a “buy” rating to a “neutral” rating in a report on Wednesday, September 17th. Canaccord Genuity Group lowered their price target on Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a report on Friday, August 1st. Zacks Research upgraded Vericel from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 14th. Truist Financial lowered their price target on Vericel from $46.00 to $41.00 and set a “buy” rating for the company in a report on Wednesday, October 15th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Vericel in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Vericel currently has an average rating of “Moderate Buy” and an average target price of $58.40.

Institutional Trading of Vericel

Several large investors have recently modified their holdings of VCEL. Sei Investments Co. grew its stake in shares of Vericel by 257.9% during the second quarter. Sei Investments Co. now owns 221,999 shares of the biotechnology company’s stock valued at $9,446,000 after acquiring an additional 159,975 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Vericel by 22.9% during the second quarter. Bank of America Corp DE now owns 438,228 shares of the biotechnology company’s stock valued at $18,647,000 after acquiring an additional 81,600 shares in the last quarter. Raymond James Financial Inc. grew its stake in shares of Vericel by 20.6% during the second quarter. Raymond James Financial Inc. now owns 432,440 shares of the biotechnology company’s stock valued at $18,400,000 after acquiring an additional 73,779 shares in the last quarter. Soleus Capital Management L.P. acquired a new stake in shares of Vericel during the second quarter valued at about $2,168,000. Finally, Goldman Sachs Group Inc. grew its stake in shares of Vericel by 13.6% during the first quarter. Goldman Sachs Group Inc. now owns 371,486 shares of the biotechnology company’s stock valued at $16,576,000 after acquiring an additional 44,333 shares in the last quarter.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.